恩威医药
(301331)
| 流通市值：10.43亿 | | | 总市值：32.42亿 |
| 流通股本：3310.17万 | | | 总股本：1.03亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 196,499,491.35 | 812,127,431.13 | 560,341,100.4 | 388,149,545.27 |
| 营业收入 | 196,499,491.35 | 812,127,431.13 | 560,341,100.4 | 388,149,545.27 |
| 二、营业总成本 | 183,733,734.69 | 763,172,474.47 | 534,869,746.2 | 365,609,056.27 |
| 营业成本 | 101,928,907.9 | 399,443,939.66 | 274,836,889.56 | 186,797,596.56 |
| 税金及附加 | 2,056,668.59 | 12,555,058.15 | 9,447,037.16 | 6,466,080.53 |
| 销售费用 | 60,842,025.31 | 267,145,001.09 | 187,705,109.1 | 132,079,798.46 |
| 管理费用 | 17,722,947.71 | 76,226,203.19 | 58,126,682.55 | 37,261,675.14 |
| 研发费用 | 1,085,549.14 | 9,073,915.83 | 5,770,697.03 | 3,367,770.05 |
| 财务费用 | 97,636.04 | -1,271,643.45 | -1,016,669.2 | -363,864.47 |
| 其中:利息费用 | 828,750 | 2,426,424.62 | 1,476,158.26 | 568,769.37 |
| 其中:利息收入 | 791,658.07 | 4,090,693.9 | 2,831,648.23 | 1,236,062.81 |
| 加:投资收益 | 1,132,468.42 | 3,494,421.27 | 2,400,428.63 | 1,848,863.59 |
| 资产处置收益 | - | -263,488.07 | -166,771.5 | -121,924.03 |
| 资产减值损失(新) | 2,643,099.55 | -3,877,937 | -1,225,604.44 | -1,179,122.47 |
| 信用减值损失(新) | 601,274.29 | -1,506,376.82 | -511,935.99 | -1,681,667.22 |
| 其他收益 | 1,053,346.16 | 2,884,939.95 | 2,565,868.93 | 1,942,458.74 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 18,195,945.08 | 49,686,515.99 | 28,533,339.83 | 23,349,097.61 |
| 加:营业外收入 | 1,506.8 | 223,998.78 | 211,685.68 | 6,121.2 |
| 减:营业外支出 | 210,812.14 | 3,226,680.45 | 3,222,443.46 | 417,364.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 17,986,639.74 | 46,683,834.32 | 25,522,582.05 | 22,937,854.76 |
| 减:所得税费用 | 1,681,512.85 | 9,186,289.97 | 3,500,619.47 | 5,003,412.03 |
| 六、净利润 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 | 17,934,442.73 |
| 持续经营净利润 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 | 17,934,442.73 |
| 归属于母公司股东的净利润 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 | 17,934,442.73 |
| (一)基本每股收益 | 0.16 | 0.37 | 0.22 | 0.18 |
| (二)稀释每股收益 | 0.16 | 0.37 | 0.22 | 0.18 |
| 九、综合收益总额 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 | 17,934,442.73 |
| 归属于母公司股东的综合收益总额 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 | 17,934,442.73 |
| 公告日期 | 2025-04-21 | 2025-04-21 | 2024-10-24 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |